Should I buy or sell Galecto stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLTO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLTO, but not buy additional shares or sell existing shares. View GLTO analyst ratings or view top-rated stocks .

What is Galecto's stock price target for 2024?

5 Wall Street research analysts have issued 1-year price targets for Galecto's stock. Their GLTO share price targets range from $2.00 to $12.00. On average, they anticipate the company's stock price to reach $5.33 in the next year. This suggests a possible upside of 672.4% from the stock's current price. View analysts price targets for GLTO or view top-rated stocks among Wall Street analysts .

How have GLTO shares performed in 2024?

Galecto's stock was trading at $0.72 at the start of the year. Since then, GLTO shares have decreased by 4.1% and is now trading at $0.6905. View the best growth stocks for 2024 here .

Are investors shorting Galecto?

Galecto saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 31,500 shares, an increase of 74.0% from the March 15th total of 18,100 shares. Based on an average trading volume of 249,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company's stock are sold short. View Galecto's Short Interest .

When is Galecto's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our GLTO earnings forecast .

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) posted its earnings results on Friday, March, 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08.

When did Galecto IPO?

Galecto (GLTO) raised $86 million in an initial public offering on Thursday, October 29th 2020. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of Galecto?

Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLTO

Galecto (GLTO) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free GLTO Stock Alerts

$0.68

-0.04 (-5.42%)

(As of 12:52 PM ET)

Compare

Today's Range: $0.68
▼
$0.70
50-Day Range: $0.62
▼
$0.89
52-Week Range: $0.50
▼
$3.70

Volume: 45,254 shs
Average Volume: 234,144 shs
Market Capitalization: $18.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.33

Get Galecto alerts:

Galecto MarketRank™ Stock Analysis

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 672.4% Upside
$5.33 Price Target
Short Interest: Healthy
0.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.20) to ($1.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.42 out of 5 stars

Medical Sector

716th out of 918 stocks

Pharmaceutical Preparations Industry

325th out of 423 stocks

3.1

Analyst's Opinion

Consensus Rating
Galecto has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Galecto has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.16% of the float of Galecto has been sold short.
Short Interest Ratio / Days to Cover
Galecto has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Galecto has recently increased by 74.03%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Galecto does not currently pay a dividend.
Dividend Growth
Galecto does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLTO.

2.0

News and Social Media Coverage

News Sentiment
Galecto has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Galecto this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galecto insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.10% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.20% of the stock of Galecto is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Galecto are expected to decrease in the coming year, from ($1.20) to ($1.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galecto is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galecto is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galecto has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Galecto Stock (NASDAQ:GLTO)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

GLTO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLTO Stock News Headlines

April 18, 2024 | americanbankingnews.com

Galecto (NASDAQ:GLTO) Shares Down 1.9%

March 15, 2024 | msn.com

GLTO Stock Earnings: Galecto Beats EPS for Q4 2023

April 19, 2024 | DTI (Ad)

Here’s how to start a “Weekend Side Hustle” from your sofa

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

February 16, 2024 | thestreet.com

Galecto Inc.

February 14, 2024 | finance.yahoo.com

Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?

January 9, 2024 | finance.yahoo.com

What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock

December 23, 2023 | finanznachrichten.de

Galecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

December 22, 2023 | msn.com

Nike, AAR And 3 Stocks To Watch Heading Into Friday

April 19, 2024 | DTI (Ad)

Here’s how to start a “Weekend Side Hustle” from your sofa

December 21, 2023 | finance.yahoo.com

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

October 23, 2023 | finance.yahoo.com

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

October 5, 2023 | msn.com

Galecto (GLTO) Price Target Increased by 13.16% to 5.48

October 2, 2023 | finanznachrichten.de

Galecto, Inc.: Galecto Announces Plans to Explore Strategic Alternatives

September 30, 2023 | msn.com

HC Wainwright & Co. Downgrades Galecto (GLTO)

September 27, 2023 | bizjournals.com

Weeks after dropping lung disease drug, Galecto lays off most of staff, explores sale

September 26, 2023 | finance.yahoo.com

Galecto Announces Plans to Explore Strategic Alternatives

September 14, 2023 | msn.com

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

August 31, 2023 | finance.yahoo.com

Galecto to Present at Investor Conferences in September

August 22, 2023 | msn.com

HC Wainwright & Co. Maintains Galecto (GLTO) Buy Recommendation

August 21, 2023 | markets.businessinsider.com

Expert Ratings for Galecto

August 17, 2023 | finance.yahoo.com

Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More

August 16, 2023 | marketwatch.com

Galecto Ends Development of Lead Candidate After IPF Study Failure >GLTO

August 16, 2023 | finance.yahoo.com

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

August 15, 2023 | msn.com

SVB Leerink Downgrades Galecto (GLTO)

August 15, 2023 | bizjournals.com

Galecto shares plummet after biotech drops lung disease drug

August 15, 2023 | msn.com

Why Is Galecto Stock Plummeting Today?

August 15, 2023 | seekingalpha.com

Galecto to drop lung disease drug after Phase 2 setback

See More Headlines

Receive GLTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/19/2024
Next Earnings (Estimated): 4/26/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GLTO
CUSIP: N/A
CIK: 1800315
Web: galecto.com
Phone: 45-7070-5210
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.33
High Stock Price Target: $12.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +640.7%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -93.68%
Return on Assets: -72.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.31
Quick Ratio: 6.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.19 per share
Price / Book: 0.61

Miscellaneous

Outstanding Shares: 27,110,000
Free Float: 23,832,000
Market Cap: $19.52 million
Optionable: Optionable
Beta: 1.24

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Hans T. Schambye M.D. (Age 58)
Ph.D., Co-Founder, President, CEO & Director
Comp: $700.13k
Mr. Jonathan P. Freve CPA (Age 46)
CPA, Chief Financial Officer
Comp: $604.93k
Mr. Ulf J. Nilsson
Co-Founder
Dr. Hakon Leffler
Co-Founder
Prof. Tariq Sethi B.Sc.
FRCP, M.A., M.D., Ph.D., Co-Founder
Mr. Garrett Winslow Esq. (Age 45)
Senior VP, General Counsel & Corporate Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLTO Stock Analysis - Frequently Asked Questions

Should I buy or sell Galecto stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLTO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLTO, but not buy additional shares or sell existing shares.
View GLTO analyst ratings or view top-rated stocks.
What is Galecto's stock price target for 2024?: 5 Wall Street research analysts have issued 1-year price targets for Galecto's stock. Their GLTO share price targets range from $2.00 to $12.00. On average, they anticipate the company's stock price to reach $5.33 in the next year. This suggests a possible upside of 672.4% from the stock's current price.
View analysts price targets for GLTO or view top-rated stocks among Wall Street analysts.
How have GLTO shares performed in 2024?: Galecto's stock was trading at $0.72 at the start of the year. Since then, GLTO shares have decreased by 4.1% and is now trading at $0.6905.
View the best growth stocks for 2024 here.
Are investors shorting Galecto?: Galecto saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 31,500 shares, an increase of 74.0% from the March 15th total of 18,100 shares. Based on an average trading volume of 249,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company's stock are sold short.
View Galecto's Short Interest.

When is Galecto's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our GLTO earnings forecast.
How were Galecto's earnings last quarter?: Galecto, Inc. (NASDAQ:GLTO) posted its earnings results on Friday, March, 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08.
When did Galecto IPO?: Galecto (GLTO) raised $86 million in an initial public offering on Thursday, October 29th 2020. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and Kempen & Co. was co-manager.
How do I buy shares of Galecto?: Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLTO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial